All In Biotech

Drug Trial Radar · NCT03809481

Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban

Open-Label, Randomised, Active Controlled, Multi-Centre Ph 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Acute HIT

Last checked: Nov 20, 2026Latest source record: Dec 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

7

Actual

Start

May 16, 2019

Primary completion

Jun 10, 2022

Study completion Jun 10, 2022

Sponsor

Lead sponsor
Aspen Global IncorporatedIndustry
Sponsor type
Industry
First posted
Jan 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 weeks, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study)

Conditions

  • Heparin-induced Thrombocytopenia

Interventions

  • Danaparoid SodiumDrug

    inhibits thrombin generation by indirect anti-Xa inhibition and direct inhibition of factor IX activation

  • ArgatrobanDrug

    Synthetic direct thrombin inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite Efficacy ResponseTime frame: Day 44

Locations

35 sites in 9 countries. Site status is shown where the registry gives one.

  • Shands University of Florida

    Gainesville, Florida

  • University of Minnesota Medical Center

    Minneapolis, Minnesota

  • Duke University Medical Center

    Durham, North Carolina

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University Clinical Centre of the Republic of Srpska, Clinic for cardiology

    Banja Luka, Bosnia and Herzegovina

  • University Clinical Centre of the Republic of Srpska, Lung Clinic

    Banja Luka, Bosnia and Herzegovina

  • Clinical Center University of Sarajevo, Clinic for Heart, Blood Vessels and Rheumatic Diseases

    Sarajevo, Bosnia and Herzegovina

  • Clinical Center University of Sarajevo, Clinic for Lung Diseases

    Sarajevo, Bosnia and Herzegovina

  • Clinical Center of the Republic of Srpska, Medical Intesnive Care Unit

    Banja Luka, Republika Srpska, Bosnia and Herzegovina

  • Jewish General Hospital

    Montreal, Canada

  • CHU St Etienne; Avenue Albert Raimond

    Saint-Priest-en-Jarez, Auvergne-Rhône-Alpes, France

  • DIJON University Hospital

    Dijon, Burgundy, France

  • Centre Hospitalier Universitaire Amiens Picardie

    Amiens, Somme, France

  • University Hospital Greifswald Dpt. of Hematology

    Greifswald, Germany

  • Zentrum für Klinische Transfusionsmedizin

    Tübingen, Germany

  • Vivantes Klinikum im Friedrichhain Hämophiliezentrum, Gerinnungssprechstunde Landsberger Allee 49

    Berlin, Berlin-Brandenburg, Germany

  • Universitätsklinikum Gießen und Marburg GmbH, Klinik für Herz-, Kinderherz- und Gefäßchirurgie Standort Gießen

    Giesen, Lower Saxony, Germany

  • Städtisches Klinkum Dresden

    Dresden, Saxony, Germany

  • Universitatstklinikum Halle (Saale), Medizinische Klinik III

    Halle, Saxony-Anhalt, Germany

  • Instituto Scientifico San Raffaele- Servizio Coagulazione e Centro Trombosi

    Milan, Italy

  • Azienda Ospedaliero Universitaria S.Orsola-Malpighi - UO Angiologia e Malattie della Coagulazione

    Bologna, Emilia-Romagna, Italy

  • AOU Careggi, SOD Malattie Aterotrombotiche

    Florence, Florence, Italy

  • ASST Papa Giovanni XIII, Servizio di Immunoematologia e Medicina Trasfusionale

    Bergamo, Lombardy, Italy

  • Centrum Medyczne HCP Sp. z o.o. Szpital im. Św. Jana Pawła II

    Poznan, Poland

  • Wojewódzki Szpital Zespolony im. L. Rydygiera

    Torun, Poland

  • First City Hospital N.A. E.E. Volosevich

    Arkhangelsk, Russia

  • Moscow City Hospital 67

    Moscow, Russia

  • Oncology Center

    Omsk, Russia

  • Regional Hospital after N.N Burdenko

    Penza, Russia

  • Clinical Hospital № 122 N. A. L.G. Sokolov

    Saint Petersburg, Russia

  • Clinical Centre of Serbia, Clinic for Emergency Internal Medicine

    Belgrade, Serbia

  • Clinical centre of Serbia, Clinic for Pulmonology

    Belgrade, Serbia

  • Instiute of Cardiovascular Diseases "Dedinje"

    Belgrade, Serbia

  • The Institute for Pulmonary Disease of Vojvodina, Pulmonary thromboembolism department

    Novi Sad, Sremska Kamenica, Serbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.